Japanese encephalitis virus degrades TRAF3 to suppress type I interferon and promote viral replication through NS5 and host TUFM proteins

Read full text
Authors: Xingya Wang, C. Xinhong Wang, Xinyu Yang, Wenzhen Qin, Xuelan Liu, Hai Yu, Wu Tong, Guangzhi Tong, Tongling Shan, Ning Kong, Guangxu Xing, Hao Zheng
Cited by: 1
References: 29

Abstract

Japanese encephalitis (JE), caused by the Japanese encephalitis virus (JEV), remains a major global health concern. A deeper understanding of how JEV manipulates host antiviral responses is critical for developing more effective therapeutic strategies. In this study, we identified a novel immune evasion mechanism through which JEV suppresses host innate immunity to facilitate viral replication. Specifically, JEV infection induces the expression of the host translation elongation factor TUFM by activating the transcription factor JUN. We demonstrated that TUFM promotes JEV replication, while TUFM silencing significantly reduces viral load. Mechanistically, TUFM acts as a scaffold to recruit the E3 ubiquitin ligase Parkin and the autophagy receptor p62, thereby mediating selective autophagy-dependent degradation of the key innate immune adaptor TRAF3. Intriguingly, the viral NS5 protein was also found to promote TRAF3 degradation via a similar autophagy-dependent pathway, suggesting a coordinated strategy between viral and host factors. Since TRAF3 is essential for the activation of IRF3 and downstream type I interferon signaling, its degradation effectively blunts antiviral innate immune responses. Collectively, our findings reveal a previously unrecognized mechanism by which JEV subverts host innate immunity through the TUFM-NS5-Parkin-p62-TRAF3 axis to promote immune evasion and viral propagation.

Fields of Study & Subjects

Mosquito-borne diseases and control Autophagy in Disease and Therapy interferon and immune responses

Publication details

Journal / source
Veterinary Research
Publisher
Springer Science and Business Media LLC
Volume
57
Issue
1
Publication date
4 April 2026
Language
EN